A report from Canaccord reiterates its Buy rating and $28 price target on AVEO Pharmaceuticals AVEO.
The report states, “Ahead of a December 7 ODAC meeting to discuss the merits of the NDA for Pfizer's axitinib, a potential competitor to AVEO's tivozanib in advanced renal cell carcinoma (RCC), we maintain our BUY rating on AVEO.”
AVEO closed Friday at $14.99.
RCCReady Capital Corporation 5.75% Senior Notes due 2026
$24.590.57%
Edge Rankings
Momentum-
Growth-
Quality-
Value-
Price Trend
Short
Medium
Long
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in